Joanne M. Donovan sold $2.1M of EWTX
CMO at Edgewise Therapeutics, Inc.. 55,230 shares at an average of $37.88, traded May 4, 2026, filed May 5, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.1M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.1%, 3m +17.6%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001644087-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 4, 2026 | SOpen-market sale Common Stock10b5-1 | -5,230 | $31.29 | $164k | 4,367 | May 5, 2026 |
| May 5, 2026 | MOption exercise Common Stock | +50,000 | $7.08 | $354k | 54,367 | May 5, 2026 |
| May 5, 2026 | SOpen-market sale Common Stock10b5-1 | -50,000 | $38.57 | $1.9M | 4,367 | May 5, 2026 |
| May 5, 2026 | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 75,000 | May 5, 2026 |
Related signals
Other insiders at Edgewise Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | Edgewise Therapeutics, Inc. | Behrad Derakhshan Chief Business Officer | $223k 5,100 shares | -14% | |
| 31Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $413k 9,441 shares | -52% | |
| 57Moderate | Edgewise Therapeutics, Inc. | Kevin Koch President and CEO | $785k 17,971 shares | -26% | |
| 32Weak | Edgewise Therapeutics, Inc. | John R Moore General Counsel | $220k 5,016 shares | -22% | |
| 33Weak | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $258k 5,901 shares | -16% | |
| 25Weak | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $7.9M 200,000 shares | -89% | |
| 24Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $926k 28,662 shares | -75% | |
| 21Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $685k 21,338 shares | -69% | |
| 33Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $507k 16,358 shares | -63% | |
| 25Weak | Edgewise Therapeutics, Inc. | Badreddin Edris director | $3.4M 115,471 shares | -85% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.